Press Releases

Year

June 21, 2018

Surface Oncology Recognized as one of the “Best Places to Work” by Boston Business Journal

June 12, 2018

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930

June 11, 2018

Surface Oncology to be Added to the Russell 3000 Index and Russell 2000 Index

June 8, 2018

Surface Oncology to Present at Goldman Sachs 39th Annual Global Healthcare Conference

May 29, 2018

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2018

May 15, 2018

Surface Oncology to Present at 2018 UBS Global Healthcare Conference

April 23, 2018

Surface Oncology Announces Closing of $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement

April 18, 2018

Surface Oncology Announces $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement

March 20, 2018

Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231

February 22, 2018

Surface Oncology Expands Board Of Directors